Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 198

1.

Murine Oviductal High-Grade Serous Carcinomas Mirror the Genomic Alterations, Gene Expression Profiles, and Immune Microenvironment of Their Human Counterparts.

McCool K, Freeman ZT, Zhai Y, Wu R, Hu K, Liu CJ, Tomlins SA, Fearon ER, Magnuson B, Kuick R, Cho KR.

Cancer Res. 2019 Dec 5. pii: canres.2558.2019. doi: 10.1158/0008-5472.CAN-19-2558. [Epub ahead of print]

PMID:
31806642
2.

Histological characterization of aldosterone-producing adrenocortical adenomas with different somatic mutations.

Ono Y, Yamazaki Y, Omata K, Else T, Tomlins SA, Rhayem Y, Williams TA, Reincke M, Carling T, Monticone S, Mulatero P, Beuschlein F, Ito S, Satoh F, Rainey WE, Sasano H.

J Clin Endocrinol Metab. 2019 Dec 2. pii: dgz235. doi: 10.1210/clinem/dgz235. [Epub ahead of print]

PMID:
31789380
3.

Discordant and heterogeneous clinically relevant genomic alterations in circulating tumor cells vs plasma DNA from men with metastatic castration resistant prostate cancer.

Gupta S, Hovelson DH, Kemeny G, Halabi S, Foo WC, Anand M, Somarelli JA, Tomlins SA, Antonarakis ES, Luo J, Dittamore RV, George DJ, Rothwell C, Nanus DM, Armstrong AJ, Gregory SG.

Genes Chromosomes Cancer. 2019 Nov 9. doi: 10.1002/gcc.22824. [Epub ahead of print]

PMID:
31705765
4.

Circulating Tumor Cell-Based Molecular Classifier for Predicting Resistance to Abiraterone and Enzalutamide in Metastatic Castration-Resistant Prostate Cancer.

Chung JS, Wang Y, Henderson J, Singhal U, Qiao Y, Zaslavsky AB, Hovelson DH, Spratt DE, Reichert Z, Palapattu GS, Taichman RS, Tomlins SA, Morgan TM.

Neoplasia. 2019 Aug;21(8):802-809. doi: 10.1016/j.neo.2019.06.002. Epub 2019 Jul 2.

5.

DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway.

Kothari V, Goodwin JF, Zhao SG, Drake JM, Yin Y, Chang SL, Evans JR, Wilder-Romans K, Gabbara K, Dylgjeri E, Chou J, Sun G, Tomlins SA, Mehra R, Hege K, Filvaroff EH, Schaeffer EM, Karnes RJ, Quigley DA, Rathkopf DE, He HH, Speers C, Spratt DE, Gilbert LA, Ashworth A, Chinnaiyan AM, Raj GV, Knudsen KE, Feng FY.

Clin Cancer Res. 2019 Sep 15;25(18):5608-5622. doi: 10.1158/1078-0432.CCR-18-2387. Epub 2019 Jul 2.

PMID:
31266829
6.

Identification of TP53RK-Binding Protein (TPRKB) Dependency in TP53-Deficient Cancers.

Goswami MT, VanDenBerg KR, Han S, Wang LL, Singh B, Weiss T, Barlow M, Kamberov S, Wilder-Romans K, Rhodes DR, Feng FY, Tomlins SA.

Mol Cancer Res. 2019 Aug;17(8):1652-1664. doi: 10.1158/1541-7786.MCR-19-0144. Epub 2019 May 20.

PMID:
31110156
7.

Informing a Risk Prediction Model for Binary Outcomes with External Coefficient Information.

Cheng W, Taylor JMG, Gu T, Tomlins SA, Mukherjee B.

J R Stat Soc Ser C Appl Stat. 2019 Jan;68(1):121-139. doi: 10.1111/rssc.12306. Epub 2018 Aug 13.

PMID:
31105344
8.

Merging new-age biomarkers and nanodiagnostics for precision prostate cancer management.

Koo KM, Mainwaring PN, Tomlins SA, Trau M.

Nat Rev Urol. 2019 May;16(5):302-317. doi: 10.1038/s41585-019-0178-2. Review.

PMID:
30962568
9.

TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Kaur HB, Lu J, Guedes LB, Maldonado L, Reitz L, Barber JR, De Marzo AM, Tomlins SA, Sfanos KS, Eisenberger M, Schaeffer EM, Joshu CE, Lotan TL.

Hum Pathol. 2019 May;87:95-102. doi: 10.1016/j.humpath.2019.02.006. Epub 2019 Mar 6.

PMID:
30851334
10.

SPINK1 expression is enriched in African American prostate cancer but is not associated with altered immune infiltration or oncologic outcomes post-prostatectomy.

Faisal FA, Kaur HB, Tosoian JJ, Tomlins SA, Schaeffer EM, Lotan TL.

Prostate Cancer Prostatic Dis. 2019 Dec;22(4):552-559. doi: 10.1038/s41391-019-0139-0. Epub 2019 Mar 8.

PMID:
30850708
11.

Impact of the SPOP Mutant Subtype on the Interpretation of Clinical Parameters in Prostate Cancer.

Liu D, Takhar M, Alshalalfa M, Erho N, Shoag J, Jenkins RB, Karnes RJ, Ross AE, Schaeffer EM, Rubin MA, Trock B, Klein EA, Den RB, Tomlins SA, Spratt DE, Davicioni E, Sboner A, Barbieri CE.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00036. Epub 2018 Jul 24.

12.

Genetic Characteristics of Aldosterone-Producing Adenomas in Blacks.

Nanba K, Omata K, Gomez-Sanchez CE, Stratakis CA, Demidowich AP, Suzuki M, Thompson LDR, Cohen DL, Luther JM, Gellert L, Vaidya A, Barletta JA, Else T, Giordano TJ, Tomlins SA, Rainey WE.

Hypertension. 2019 Apr;73(4):885-892. doi: 10.1161/HYPERTENSIONAHA.118.12070.

PMID:
30739536
13.

Tubulocystic renal cell carcinoma: a distinct clinicopathologic entity with a characteristic genomic profile.

Sarungbam J, Mehra R, Tomlins SA, Smith SC, Jayakumaran G, Al-Ahmadie H, Gopalan A, Sirintrapun SJ, Fine SW, Zhang Y, Amin MB, Reuter VE, Chen YB, Tickoo SK.

Mod Pathol. 2019 May;32(5):701-709. doi: 10.1038/s41379-018-0185-5. Epub 2019 Jan 8.

PMID:
30622286
14.

Multiclonality and Marked Branched Evolution of Low-Grade Endometrioid Endometrial Carcinoma.

Lazo de la Vega L, Samaha MC, Hu K, Bick NR, Siddiqui J, Hovelson DH, Liu CJ, Carter CS, Cho KR, Sciallis AP, Tomlins SA.

Mol Cancer Res. 2019 Mar;17(3):731-740. doi: 10.1158/1541-7786.MCR-18-1178. Epub 2019 Jan 4.

PMID:
30610106
15.

Clinical and Genomic Implications of Luminal and Basal Subtypes Across Carcinomas.

Zhao SG, Chen WS, Das R, Chang SL, Tomlins SA, Chou J, Quigley DA, Dang HX, Barnard TJ, Mahal BA, Gibb EA, Liu Y, Davicioni E, Duska LR, Posadas EM, Jolly S, Spratt DE, Nguyen PL, Maher CA, Small EJ, Feng FY.

Clin Cancer Res. 2019 Apr 15;25(8):2450-2457. doi: 10.1158/1078-0432.CCR-18-3121. Epub 2018 Dec 20.

PMID:
30573691
16.

Somatic mutations in adrenocortical carcinoma with hyperaldosteronism.

Mouat IC, Omata K, McDaniel AS, Hattangady N, Talapatra D, Cani AK, Hovelson DH, Tomlins SA, Rainey W, Hammer G, Giordano TJ, Else T.

Endocr Relat Cancer. 2018 Nov 1. pii: ERC-18-0385.R2. doi: 10.1530/ERC-18-0385. [Epub ahead of print]

PMID:
30475217
17.

Transcriptomic heterogeneity in multifocal prostate cancer.

Salami SS, Hovelson DH, Kaplan JB, Mathieu R, Udager AM, Curci NE, Lee M, Plouffe KR, de la Vega LL, Susani M, Rioux-Leclercq N, Spratt DE, Morgan TM, Davenport MS, Chinnaiyan AM, Cyrta J, Rubin MA, Shariat SF, Tomlins SA, Palapattu GS.

JCI Insight. 2018 Nov 2;3(21). pii: 123468. doi: 10.1172/jci.insight.123468.

18.

Cellular and Genetic Causes of Idiopathic Hyperaldosteronism.

Omata K, Satoh F, Morimoto R, Ito S, Yamazaki Y, Nakamura Y, Anand SK, Guo Z, Stowasser M, Sasano H, Tomlins SA, Rainey WE.

Hypertension. 2018 Oct;72(4):874-880. doi: 10.1161/HYPERTENSIONAHA.118.11086.

19.

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer.

Quigley DA, Dang HX, Zhao SG, Lloyd P, Aggarwal R, Alumkal JJ, Foye A, Kothari V, Perry MD, Bailey AM, Playdle D, Barnard TJ, Zhang L, Zhang J, Youngren JF, Cieslik MP, Parolia A, Beer TM, Thomas G, Chi KN, Gleave M, Lack NA, Zoubeidi A, Reiter RE, Rettig MB, Witte O, Ryan CJ, Fong L, Kim W, Friedlander T, Chou J, Li H, Das R, Li H, Moussavi-Baygi R, Goodarzi H, Gilbert LA, Lara PN Jr, Evans CP, Goldstein TC, Stuart JM, Tomlins SA, Spratt DE, Cheetham RK, Cheng DT, Farh K, Gehring JS, Hakenberg J, Liao A, Febbo PG, Shon J, Sickler B, Batzoglou S, Knudsen KE, He HH, Huang J, Wyatt AW, Dehm SM, Ashworth A, Chinnaiyan AM, Maher CA, Small EJ, Feng FY.

Cell. 2018 Oct 18;175(3):889. doi: 10.1016/j.cell.2018.10.019. No abstract available.

20.

Association of ERG/PTEN status with biochemical recurrence after radical prostatectomy for clinically localized prostate cancer.

Mehra R, Salami SS, Lonigro R, Bhalla R, Siddiqui J, Cao X, Spratt DE, Palapattu GS, Palanisamy N, Wei JT, Chinnaiyan AM, Tomlins SA.

Med Oncol. 2018 Oct 5;35(12):152. doi: 10.1007/s12032-018-1212-6.

Supplemental Content

Loading ...
Support Center